TY - JOUR
T1 - Crystal structure of the 20 S proteasome:TMC-95A complex
T2 - A non-covalent proteasome inhibitor
AU - Groll, Michael
AU - Koguchi, Yutaka
AU - Huber, Robert
AU - Kohno, Jun
N1 - Funding Information:
We thank Dr G. Leonard (ESRF, Grenoble, France) for the help with synchrotron data collection, S. Körner and Dr F. Siedler (MPI für Biochemie, Martinsried, Germany) for providing assistance with mass spectrometry, and J. Richardson for advice. The work was supported by the Deutsche Forschungsgemeinschaft (SFB469 and Schwerpunkt Proteasome).
PY - 2001/8/17
Y1 - 2001/8/17
N2 - The 20 S proteasome core particle (CP), a multicatalytic protease, is involved in a variety of biologically important processes, including immune response, cell-cycle control, metabolic adaptation, stress response and cell differentiation. Therefore, selective inhibition of the CP will be one possible way to influence these essential pathways. Recently, a new class of specific proteasome inhibitors, TMC-95s, was investigated and we now present a biochemical and crystallographic characterisation of the yeast proteasome core particle in complex with the natural product TMC-95A. This unusual heterocyclic compound specifically blocks the active sites of CPs non-covalently, without modifying the nucleophilic Thr1 residue. The inhibitor is bound to the CP by specific hydrogen bonds with the main-chain atoms of the protein. Analysis of the crystal structure of the complex has revealed which portions of TMC-95s are essential for binding to the proteasome. This will form the basis for the development of synthetic selective proteasome inhibitors as promising candidates for anti-tumoral or anti-inflammatory drugs.
AB - The 20 S proteasome core particle (CP), a multicatalytic protease, is involved in a variety of biologically important processes, including immune response, cell-cycle control, metabolic adaptation, stress response and cell differentiation. Therefore, selective inhibition of the CP will be one possible way to influence these essential pathways. Recently, a new class of specific proteasome inhibitors, TMC-95s, was investigated and we now present a biochemical and crystallographic characterisation of the yeast proteasome core particle in complex with the natural product TMC-95A. This unusual heterocyclic compound specifically blocks the active sites of CPs non-covalently, without modifying the nucleophilic Thr1 residue. The inhibitor is bound to the CP by specific hydrogen bonds with the main-chain atoms of the protein. Analysis of the crystal structure of the complex has revealed which portions of TMC-95s are essential for binding to the proteasome. This will form the basis for the development of synthetic selective proteasome inhibitors as promising candidates for anti-tumoral or anti-inflammatory drugs.
KW - Drug design
KW - Multicatalytic complex
KW - Protease
KW - Proteasome
KW - Ubiquitin pathway
UR - http://www.scopus.com/inward/record.url?scp=0035902778&partnerID=8YFLogxK
U2 - 10.1006/jmbi.2001.4869
DO - 10.1006/jmbi.2001.4869
M3 - Article
C2 - 11493007
AN - SCOPUS:0035902778
SN - 0022-2836
VL - 311
SP - 543
EP - 548
JO - Journal of Molecular Biology
JF - Journal of Molecular Biology
IS - 3
ER -